Table 1. Summary of CTCL patient... | American Society of Hematology

Table 1.

Summary of CTCL patient characteristics

Patient ID	Sex	Age, y	Therapy during experiment time period	Previous therapy	Experiment time period	Most recent prior treatment	FISH
1	M	72	ECP, IFN-α, BEX	None	5/2019-	–	Normal for screened genes
1	M	72	ECP, IFN-α, BEX	None	10/2019	–	Normal for screened genes
2	M	78	ECP, BEX, N2M	None	1/2019-	–	Normal for screened genes
2	M	78	ECP, BEX, N2M	None	8/2019	–	Normal for screened genes
3	F	71	ECP, BEX	ACIT	2/2019	–	–
4	F	67	ROMI, BEX	ECP	11/2018-9/2019	–	Amp: None
4	F	67	ROMI, BEX	ECP	11/2018-9/2019	–	Del: TP53, ARID1A, ZEB1, DNMT3A, FAS
5	F	77	ECP, BEX	MTX, VORI, ROMI	8/2019	VORI: 07/2019	Normal for screened genes
5	F	77	ECP, BEX	MTX, VORI, ROMI	8/2019	MTX, ROMI: 08/2019	Normal for screened genes
6	F	41	EPOCH, ROMI, MOGA	ECP, BEX, N2M, IMQ, BRENT	10/2018-	BEX, N2M: 9/2018	–
6	F	41	EPOCH, ROMI, MOGA	ECP, BEX, N2M, IMQ, BRENT	9/2019	BRENT: 11/2018	–
7	M	83	ECP, BEX	None	5/2019-	–	Amp: MYC
7	M	83	ECP, BEX	None	10/2019	–	Del: None
8	F	63	ROMI	ECP, IFN-α, BEX	1/2019-	BEX: 04/2017	Amp: MYC, STAT3
8	F	63	ROMI	ECP, IFN-α, BEX	2/2020	BEX: 04/2017	Del: TP53, ZEB1, DNMT3A
9	M	69	ECP, NB-UVB	None	3/2019-	–	Normal for screened genes
9	M	69	ECP, NB-UVB	None	10/2019	–	Normal for screened genes
10	M	56	ECP, BEX	DUP, prednisone, topical steroids	2/2020	DUP: 01/2020	Normal for screened genes
11	M	75	BEX	None	5/2019-	–	Amp: None
11	M	75	BEX	None	10/2019	–	Del: DNMT3A, ATM,TP53, RB1, D9Z3, ZEB1, FAS
12	F	83	ECP, BEX	MTX	8/2018	MTX: 03/2018	Amp: MYC, STAT3
12	F	83	ECP, BEX	MTX	8/2018	MTX: 03/2018	Del: TP53
13	M	80	ECP, NB-UVB, IFN-α, BEX	NB-UVB	6/2018	ROMI: 2016	Amp: MYC, STAT3, CARD11
13	M	80	ECP, NB-UVB, IFN-α, BEX	NB-UVB	6/2018	ROMI: 2016	Del: TP53, ZEB1, DNMT3A, FAS
14	F	77	ECP, BEX	None	7/2019	–	Amp: MYC
15	M	85	ECP	None	2/2020	–	Amp: ARID1A, STAT3, ZEB1, DNMT3A, CARD11, CDKN2A, D9Z3
16	M	81	ECP	BRENT, BEX, MTX	11/2019	BRENT: 10/2018	Amp: MYC, CDKN2A, D9Z3
						BEX: 03/2019	Del: DNMT3, FAS, ATM, RB1
						MTX: 07/2019
17	M	70	ROMI	ECP, MYCO, ACIT, MTX, DUP, BEX, IFN-α	12/2018-	MYCO,ACIT, MTX, DUP: 5/2018	Amp: MYC, STAT3
17	M	70	ROMI	ECP, MYCO, ACIT, MTX, DUP, BEX, IFN-α	10/2019	BEX: 2/2019	Del: ARID1A
18	F	67	ECP, BEX, IFN-γ, IFN-α	NB-UVB	11/2018-	–	Amp: MYC
18	F	67	ECP, BEX, IFN-γ, IFN-α	NB-UVB	2/2020	–	Del: ZEB1,TP53, CDKN2A, STAT3
19	M	75	ECP, IFN-α, BEX	NB-UVB	9/2019-	–	–
19	M	75	ECP, IFN-α, BEX	NB-UVB	10/2019	–	–

Patient ID	Sex	Age, y	Therapy during experiment time period	Previous therapy	Experiment time period	Most recent prior treatment	FISH
1	M	72	ECP, IFN-α, BEX	None	5/2019-	–	Normal for screened genes
1	M	72	ECP, IFN-α, BEX	None	10/2019	–	Normal for screened genes
2	M	78	ECP, BEX, N2M	None	1/2019-	–	Normal for screened genes
2	M	78	ECP, BEX, N2M	None	8/2019	–	Normal for screened genes
3	F	71	ECP, BEX	ACIT	2/2019	–	–
4	F	67	ROMI, BEX	ECP	11/2018-9/2019	–	Amp: None
4	F	67	ROMI, BEX	ECP	11/2018-9/2019	–	Del: TP53, ARID1A, ZEB1, DNMT3A, FAS
5	F	77	ECP, BEX	MTX, VORI, ROMI	8/2019	VORI: 07/2019	Normal for screened genes
5	F	77	ECP, BEX	MTX, VORI, ROMI	8/2019	MTX, ROMI: 08/2019	Normal for screened genes
6	F	41	EPOCH, ROMI, MOGA	ECP, BEX, N2M, IMQ, BRENT	10/2018-	BEX, N2M: 9/2018	–
6	F	41	EPOCH, ROMI, MOGA	ECP, BEX, N2M, IMQ, BRENT	9/2019	BRENT: 11/2018	–
7	M	83	ECP, BEX	None	5/2019-	–	Amp: MYC
7	M	83	ECP, BEX	None	10/2019	–	Del: None
8	F	63	ROMI	ECP, IFN-α, BEX	1/2019-	BEX: 04/2017	Amp: MYC, STAT3
8	F	63	ROMI	ECP, IFN-α, BEX	2/2020	BEX: 04/2017	Del: TP53, ZEB1, DNMT3A
9	M	69	ECP, NB-UVB	None	3/2019-	–	Normal for screened genes
9	M	69	ECP, NB-UVB	None	10/2019	–	Normal for screened genes
10	M	56	ECP, BEX	DUP, prednisone, topical steroids	2/2020	DUP: 01/2020	Normal for screened genes
11	M	75	BEX	None	5/2019-	–	Amp: None
11	M	75	BEX	None	10/2019	–	Del: DNMT3A, ATM,TP53, RB1, D9Z3, ZEB1, FAS
12	F	83	ECP, BEX	MTX	8/2018	MTX: 03/2018	Amp: MYC, STAT3
12	F	83	ECP, BEX	MTX	8/2018	MTX: 03/2018	Del: TP53
13	M	80	ECP, NB-UVB, IFN-α, BEX	NB-UVB	6/2018	ROMI: 2016	Amp: MYC, STAT3, CARD11
13	M	80	ECP, NB-UVB, IFN-α, BEX	NB-UVB	6/2018	ROMI: 2016	Del: TP53, ZEB1, DNMT3A, FAS
14	F	77	ECP, BEX	None	7/2019	–	Amp: MYC
15	M	85	ECP	None	2/2020	–	Amp: ARID1A, STAT3, ZEB1, DNMT3A, CARD11, CDKN2A, D9Z3
16	M	81	ECP	BRENT, BEX, MTX	11/2019	BRENT: 10/2018	Amp: MYC, CDKN2A, D9Z3
						BEX: 03/2019	Del: DNMT3, FAS, ATM, RB1
						MTX: 07/2019
17	M	70	ROMI	ECP, MYCO, ACIT, MTX, DUP, BEX, IFN-α	12/2018-	MYCO,ACIT, MTX, DUP: 5/2018	Amp: MYC, STAT3
17	M	70	ROMI	ECP, MYCO, ACIT, MTX, DUP, BEX, IFN-α	10/2019	BEX: 2/2019	Del: ARID1A
18	F	67	ECP, BEX, IFN-γ, IFN-α	NB-UVB	11/2018-	–	Amp: MYC
18	F	67	ECP, BEX, IFN-γ, IFN-α	NB-UVB	2/2020	–	Del: ZEB1,TP53, CDKN2A, STAT3
19	M	75	ECP, IFN-α, BEX	NB-UVB	9/2019-	–	–
19	M	75	ECP, IFN-α, BEX	NB-UVB	10/2019	–	–

CTCL subtypes are subtypes at the time of diagnosis. Current therapy is defined as treatment at the time of experiment. Fluorescence in situ hybridization (FISH) panel²⁰ screened genes include: ATM, TP53, RB1, CDKN2A, MYC, ARID1A, ZEB1, STAT3, DNMT3A, CARD11, and FAS. ACIT, acitretin; BEX, bexarotene; BRENT, brentuximab; DUP, dupilumab; ECP, extracorporeal photopheresis; EPOCH, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; F, female; ID, identifier; IFN, interferon; IMQ, imiquimod; M, male; MOGA, mogamulizumab; MTX, methotrexate; MYCO, mycophenolic acid; N2M, mechlorethamine; NB-UVB, narrow band UV-B; ROMI, romidepsin; VORI, vorinostat.

View Large

This Feature Is Available To Subscribers Only